Pinealon

Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR peptide), originally isolated from Cortexin — a polypeptide fraction of porcine brain cortex — and subsequently synthesised in short-chain form in Russia. It sits within the Khavinson class of peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology, positioned toward the pineal gland and central nervous system, with stated uses in neuroprotection, cognitive enhancement, circadian regulation, geroprotection, and systemic neuroendocrine balance.

At three residues it is among the smallest bioactive peptides studied for brain health. That brevity is credited with efficient blood–brain barrier passage and, per molecular studies, nuclear entry with direct DNA interaction — the mechanistic foundation of the compound and the basis for the claim that its effects outlast a short course. The class argument is that a molecule this small also gives the immune system little to recognise.

Distinctive to the earlier entry for this compound were claims of hypothalamic–pituitary–adrenal axis modulation and pineal–hypothalamic–peripheral integration; the present entry instead grounds mechanism in tryptophan hydroxylase promoter binding, antioxidant enzyme induction, caspase-3 suppression, and ERK1/2 timing. The two accounts have not been reconciled.

Regulatory and evidentiary status: not FDA approved; nearly all published work originates from one Russian research network, dominated by preclinical and molecular studies with limited uncontrolled human observations, and no large Western trials. Independent replication is minimal.

Presentation: lyophilised 10 mg vial reconstituted with bacteriostatic water, subcutaneous or intranasal, in short cycles of 10 to 20 days repeated 2 to 3 times per year. Pinealon is also a component of the Illumi-Neuro blend on this site at a far lower per-dose amount.

Pinealon's proposed mechanism is intranuclear rather than receptor-mediated. Spectral analysis, NMR, and molecular dynamics show the Glu-Asp-Arg tripeptide partially penetrating the DNA major groove and interacting with base atoms, primarily N7 and O6 of guanine. Magnesium ions substantially enhance binding by screening phosphate backbone charge (Silanteva and colleagues, 2019).

Tryptophan hydroxylase promoter binding. Molecular docking identifies complementarity to the CCTGCC nucleotide sequence in the tryptophan hydroxylase promoter. Tryptophan hydroxylase is the rate-limiting enzyme converting tryptophan to 5-hydroxytryptophan and thence serotonin; EDR and KED peptides stimulated serotonin expression in ageing brain cortex cultures (Khavinson and colleagues, 2014). This is epigenetic regulation in the sense of altered transcriptional activity, not sequence change, and it is the best-documented arm of the mechanism.

Antioxidant enzyme induction. Increased activity of SOD2, the mitochondrial superoxide dismutase, and GPX1, glutathione peroxidase 1, constituting a first-line defence against superoxide and hydrogen peroxide. In homocysteine-exposed cultures this corresponded to reduced reactive oxygen species accumulation and fewer necrotic cells.

Anti-apoptotic action. Suppression of caspase-3, the executioner protease, demonstrated in aged rat brain under acute hypoxia. Cortexin acted predominantly through caspase-3 whereas Pinealon primarily normalised inflammatory cytokines with moderate caspase-3 effect (Mendzheritskii and colleagues, 2014).

MAPK/ERK modulation. Delayed ERK1/2 activation in neurons exposed to elevated homocysteine, extending a survival-oriented state before the stress response tips toward death.

Pineal and circadian link. Serotonin is the direct precursor of melatonin via a two-step pineal conversion, so upregulated serotonin synthesis is proposed to support melatonin production. This downstream connection is biologically coherent but has not been directly measured for Pinealon.

Other proposed actions. Kozina (2008) attributed its antihypoxic effect, the strongest among Vilon, Epitalon, Vesugen, and Pinealon, to endogenous antioxidant stimulation and possible limitation of NMDA-mediated excitotoxicity. Computational docking in 5xFAD mice identified binding sites in promoter regions of neurodegeneration-related genes (Khavinson and colleagues, 2021). The HPA axis and neuroendocrine integration claims carried over from the earlier entry lack named targets or binding data.

Neuroprotection. The strongest preclinical strand. Reduced ROS accumulation and fewer necrotic cells in homocysteine-exposed cultures; improved offspring spatial orientation and learning with fewer necrotic cerebellar neurons in prenatal hyperhomocysteinaemia (Arutjunyan and colleagues, 2012); normalised serum cytokines and reduced caspase-3 in aged rats under acute hypoxia (Mendzheritskii and colleagues, 2014); most pronounced antihypoxic effect among four regulatory peptides (Kozina, 2008). Protection against excitotoxicity and premature apoptosis is stated.

Cognition. Prevalent positive effect on Morris water maze learning in both young and old rats versus Cortexin (Mendzheritskii and colleagues, 2013); reported cognitive improvement in ageing Macaca mulatta after 10 days, published in a Russian anthropology journal.

Synaptic preservation. EDR at 200 ng/mL increased mushroom dendritic spines by 71% in amyloid-beta-exposed hippocampal neurons, restoring baseline; KED gave 20% (Kraskovskaya and colleagues, 2017). In 5xFAD mice EDR prevented spine loss, increased spine density, and enhanced neuronal differentiation (Khavinson and colleagues, 2021). In neurons derived from elderly donor fibroblasts EDR reduced oxidative DNA damage and promoted dendritogenesis with no effect on mitochondrial activity, lysosomal function, or p16 (Kraskovskaya and colleagues, 2024).

Circadian. Serotonin-precursor support for melatonin synthesis; the most commonly reported anecdotal benefit and the least rigorously evidenced. No controlled human sleep study.

Mood. Increased serotonin synthesis at the transcriptional level rather than reuptake inhibition; no comparison with SSRIs and no depression trial.

Stress adaptation, geroprotection, systemic balance. Carried from the earlier entry: HPA axis modulation improving resilience to psychological and physical stress; slowed functional CNS decline with stated potential life-extension contribution when cycled with other bioregulators; pineal–hypothalamic–peripheral neuroendocrine integration. Unsupported by named targets.

Human observations. Oral Pinealon with standard therapy in 72 patients with traumatic brain injury consequences and cerebrasthenia: improved memory, reduced headache duration and intensity, restored emotional balance, fewer cognitive testing errors, increased EEG alpha activity. Meshchaninov and colleagues (2015), 32 patients aged 41 to 83 with organic brain syndrome, no control group: anabolic effects and improved CNS activity, with unexpected pro-oxidant activity and reduced CD34+ haematopoietic stem cells; Vesugen showed stronger geroprotective effects. Named beneficiary populations from the earlier entry: age-related cognitive decline, Alzheimer's, Parkinson's, vascular dementia, traumatic brain injury and stroke, stress-related and sleep disorders, chronic fatigue and mood disorders, geroprotective protocols — stated without controlled data.

No pharmacokinetic profile, dose-finding study, or large outcome trial exists in humans, so expectations rest on animal timelines, mechanism, and anecdote.

The mechanism — transcriptional modulation and enzyme induction — predicts a slow, cumulative course. In the rhesus monkey study cognitive improvement was observed after 10 days; rat neuroprotection was measured after multi-day protocols. Nothing acute or stimulatory is expected, and users comparing it with Semax describe the contrast explicitly.

In practice, the most consistent report is improved sleep quality: easier sleep onset, more vivid or lucid dreams, better-rested waking. Cognitive reports are modest — quicker deduction, clearer and faster thought, sustained focus without mental fatigue — developing over 2 to 4 weeks, with positive outcomes more often reported by users who completed 20 to 30 day cycles. One user described improved mood, sleep, and concentration after 30 days. Mood reports are less frequent and less specific. A meaningful proportion report no discernible effect, and cost relative to subtlety is a recurrent criticism. No agreement exists on route; intranasal is preferred by some for assumed brain penetration, but no human bioavailability comparison is published.

The human observational data: 72 patients with post-traumatic brain injury consequences and cerebrasthenia on oral Pinealon plus standard therapy showed improved memory, reduced headache duration and intensity, restored emotional balance, fewer cognitive testing errors, and increased EEG alpha activity — from a Russian review, methodology not evaluated by Western peer review.

Cycling follows the bioregulator convention of 10 to 20 days on and 2 to 3 months off, on the premise that initiated gene expression changes persist after clearance. That premise is unvalidated for Pinealon by dose-duration studies, and no data describe continuous long-term use. Effects may continue after a cycle ends. Late-day dosing is associated with reported sleep disruption; morning administration avoids it.

Reconstitution. 10 mg vial with 2 mL bacteriostatic water, giving 5 mg/mL — 500 mcg per 10 insulin units, 50 mcg per unit. Recomputed draws: 100 mcg = 2 units, 200 mcg = 4 units, 300 mcg = 6 units.

Standard protocol. 100 to 300 mcg subcutaneous (or intranasal) once daily, in the morning to align with circadian rhythm, for 10 to 20 days, followed by 2 to 3 months off. At 200 mcg/day a vial yields 50 doses, well beyond a single cycle. Start at the lower end; the transcriptional mechanism gives no basis for expecting proportional dose–response and no published evidence supports higher doses. Effects accumulate across the cycle and may persist after it, consistent with the epigenetic rationale. Late-day dosing is associated with reported sleep disruption. No fasting requirement.

By application. General neuroprotection 100 to 200 mcg daily; cognitive support 200 to 300 mcg daily; sleep and circadian reset 100 to 200 mcg daily; each for 10 to 20 days.

Evidence basis. No human dose-finding study exists. Animal doses ranged from nanogram to microgram quantities. The oral doses used in the 72-patient TBI observations are not clearly reported in English-language literature. The cycling schedule is the Khavinson bioregulator convention, not the product of dose-duration studies, and continuous use is undescribed.

Divergence from the earlier entry. The previous version of this page carried a 20 mg vial in 2 mL (10 mg/mL) with a fixed first cycle of 2 mg daily for 10 days and 2 to 5 mg daily on subsequent cycles, 2 to 3 times per year, and no stated dosing time. The present 100 to 300 mcg range is roughly an order of magnitude lower and adds morning timing. Neither figure is validated in humans; the lower range is more consistent with the gene-expression mechanism and with the nanogram-to-microgram animal exposures.

Cross-product. The Illumi-Neuro blend on this site delivers 120–240 mcg of Pinealon per dose — comparable to the present standard range rather than an order of magnitude below it as the earlier entry framed it. Concurrent use should be counted toward total exposure.

Monitoring. None established; given the reduced CD34+ count in Meshchaninov and colleagues (2015), a CBC during extended use is reasonable though the clinical significance is unclear.

The evidence base is concentrated within the St. Petersburg Institute of Bioregulation and Gerontology network; independent replication is minimal. The molecular mechanism data is the most reproducible component, the clinical claims the least substantiated.

Molecular. Silanteva and colleagues (2019) used spectral analysis, NMR, and molecular dynamics to show EDR partly penetrates the DNA major groove and interacts with N7 and O6 of guanine, with Mg2+ substantially enhancing binding by screening phosphate charge. Khavinson and colleagues (2014) showed EDR and KED stimulate serotonin expression in ageing cortex cultures, with docking identifying CCTGCC in the tryptophan hydroxylase promoter as complementary. Khavinson and colleagues (2021) reported docking to promoter regions of neurodegeneration-associated genes.

In vitro. Kraskovskaya and colleagues (2017): amyloid-beta-exposed mouse hippocampal neurons; EDR at 200 ng/mL increased mushroom spines by 71%, restoring baseline; KED gave 20%. Kraskovskaya and colleagues (2024): induced neurons from elderly donor fibroblasts; EDR reduced oxidative DNA damage and promoted dendritogenesis but had no effect on mitochondrial activity, lysosomal function, or p16. Kozina (2008): most pronounced antihypoxic effect among Vilon, Epitalon, Vesugen, and Pinealon, via endogenous antioxidant enzyme induction and possible limitation of NMDA-mediated excitotoxicity.

Animal. Arutjunyan and colleagues (2012): prenatal hyperhomocysteinaemia in rats; offspring showed improved spatial learning, reduced ROS accumulation, fewer necrotic cerebellar neurons. Mendzheritskii and colleagues (2013): Morris water maze; Pinealon outperformed Cortexin in young and old rats, with caspase-3 proposed as a determinant of learning. Mendzheritskii and colleagues (2014): aged rats under acute hypoxia; Pinealon normalised cytokines and moderately affected caspase-3, whereas Cortexin primarily reduced caspase-3. Khavinson and colleagues (2021): 5xFAD mice; EDR prevented dendritic spine loss, increased spine density and mushroom spines, and enhanced neuronal differentiation. A Macaca mulatta study reported cognitive improvement after 10 days, published in a Russian anthropology journal.

Human. A review reports 72 patients with TBI consequences and cerebrasthenia receiving oral Pinealon with standard therapy: improved memory, reduced headache duration and intensity, fewer cognitive-test errors, increased alpha-wave EEG activity. Methodology not evaluated by Western peer review. Meshchaninov and colleagues (2015): 32 patients aged 41 to 83, uncontrolled; anabolic effects and improved CNS activity, Vesugen stronger as geroprotector, plus unexpected prooxidant activity and reduced CD34+ cells, no effect on chromatin condensation.

No human dose-finding, pharmacokinetic, placebo-controlled, or sleep studies exist.